» Articles » PMID: 31838274

LINC01234/MicroRNA-31-5p/MAGEA3 Axis Mediates the Proliferation and Chemoresistance of Hepatocellular Carcinoma Cells

Overview
Publisher Cell Press
Date 2019 Dec 16
PMID 31838274
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is a prevalent malignancy characterized by aggressiveness and poor prognosis; however, the molecular mechanism remains to be fully identified. Based on the analysis of The Cancer Genome Atlas (TCGA) database, melanoma-associated antigen A3 (MAGEA3) and long non-coding RNA (lncRNA) LINC01234 were upregulated in HCC and associated with poor prognosis of HCC. We investigated the mechanism of how MAGEA3 and LINC01234 influenced HCC cellular functions and cisplatin resistance. MAGEA3 depletion inhibited proliferation, invasion, and cisplatin resistance of HepG2 cells and Huh7 cells in vitro, reduced resistance-associated protein 2 (MRP2), MRP3, and multidrug resistance protein 1 (MDR-1) expression, and elevated ALB expression. RNA pull-down and RIP assays identified the binding of LINC01234 and MAGEA3 to microRNA-31-5p (miR-31-5p). LINC01234 could restore MAGEA3 expression by binding to miR-31-5p. Furthermore, we delivered plasmids into HepG2 cells and Huh7 cells to alter the expression of LINC01234 and miR-31-5p. When miR-31-5p was downregulated, the proliferation and invasion of HepG2 cells and Huh7 cells were enhanced and the cisplatin-induced apoptosis was inhibited, while LINC01234 knockdown could diminish the effects caused by miR-31-5p depletion. In summary, these data highlight the vital role of MAGEA3/LINC01234/miR-31-5p axis in the HCC progression and chemoresistance of HCC cells.

Citing Articles

SNHG15-mediated feedback loop interplays with HNRNPA1/SLC7A11/GPX4 pathway to promote gastric cancer progression.

Duan Y, Yan Y, Fu H, Dong Y, Li K, Ye Z Cancer Sci. 2024; 115(7):2269-2285.

PMID: 38720175 PMC: 11247605. DOI: 10.1111/cas.16181.


CREB3 facilitates Donafenib resistance in hepatocellular carcinoma cells via the LSD1/CoREST/p65 axis by transcriptionally activating long noncoding RNA ZFAS1.

Hou X, Xu Q, Liu R Transl Oncol. 2024; 44:101684.

PMID: 38641372 PMC: 11391036. DOI: 10.1016/j.tranon.2023.101684.


DUB3 is a MAGEA3 deubiquitinase and a potential therapeutic target in hepatocellular carcinoma.

Chen Y, Gao F, He Y, Liu M, Quan Y, Zhang P iScience. 2024; 27(3):109181.

PMID: 38414853 PMC: 10897913. DOI: 10.1016/j.isci.2024.109181.


The interplay between noncoding RNAs and drug resistance in hepatocellular carcinoma: the big impact of little things.

Fang Y, Zhang X, Huang H, Zeng Z J Transl Med. 2023; 21(1):369.

PMID: 37286982 PMC: 10249219. DOI: 10.1186/s12967-023-04238-9.


Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance.

Hashemi M, Sabouni E, Rahmanian P, Entezari M, Mojtabavi M, Raei B Cell Mol Biol Lett. 2023; 28(1):33.

PMID: 37085753 PMC: 10122325. DOI: 10.1186/s11658-023-00438-9.


References
1.
Esfandiary A, Ghafouri-Fard S . MAGE-A3: an immunogenic target used in clinical practice. Immunotherapy. 2015; 7(6):683-704. DOI: 10.2217/imt.15.29. View

2.
Guo L, Peng Y, Meng Y, Liu Y, Yang S, Jin H . Expression profiles analysis reveals an integrated miRNA-lncRNA signature to predict survival in ovarian cancer patients with wild-type BRCA1/2. Oncotarget. 2017; 8(40):68483-68492. PMC: 5620272. DOI: 10.18632/oncotarget.19590. View

3.
Wang Z, Liu L, Liu X, Hu J, Wu Y, Shi J . Genetic polymorphisms of the multidrug resistance 1 gene MDR1 and the risk of hepatocellular carcinoma. Tumour Biol. 2015; 36(9):7007-15. DOI: 10.1007/s13277-015-3407-1. View

4.
Ren Y, Han J, Cao J, Li S, Fan G . Association of MDR1 gene polymorphisms with susceptibility to hepatocellular carcinoma in the Chinese population. Asian Pac J Cancer Prev. 2013; 13(11):5451-4. DOI: 10.7314/apjcp.2012.13.11.5451. View

5.
Huang X, Gao Y, Qin J, Lu S . lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214. Am J Physiol Gastrointest Liver Physiol. 2017; 314(5):G559-G565. DOI: 10.1152/ajpgi.00242.2017. View